View Future GrowthMYND Life Sciences 過去の業績過去 基準チェック /06MYND Life Sciencesの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Jul 2024最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.お知らせ • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.お知らせ • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.お知らせ • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.お知らせ • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.お知らせ • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.お知らせ • Oct 27MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc.MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc. on October 25, 2023. The proposed merger will be preceded by independent third-party valuations of both companies. Arrangements within each company will be negotiated by subcommittees of unconflicted Directors from both CAVA and MYND and it will require affirmative votes by the Boards of Directors of both companies. It is anticipated the transaction will be completed in Q1 2024.お知らせ • Jan 10MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023.収支内訳MYND Life Sciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:MYND.F 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Jul 240-11030 Apr 240-11031 Jan 240-11031 Oct 230-21031 Jul 230-31030 Apr 230-31131 Jan 230-31131 Oct 220-42131 Jul 220-72130 Apr 220-63131 Jan 220-63131 Oct 210-43131 Oct 200000質の高い収益: MYND.Fが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: MYND.Fの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MYND.Fの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: MYND.Fの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: MYND.Fの過去 1 年間の収益成長がPharmaceuticals業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: MYND.Fは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/11 09:34終値2025/12/12 00:00収益2024/07/31年間収益2023/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MYND Life Sciences Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 10MYND Life Sciences Inc. Announces Colin Campbel Stepping Down as Chief Executive OfficerMYND Life Sciences Inc. announced that with the successful retirement of the debenture, Colin Campbell has stepped down from his CEO role, having successfully completed the goal of repositioning the Company for future success. Mr. Campbell will be retaining his role as a Director and will be supporting the process to identify a new CEO that will be effective in continuing to move the Company forward through the clinical testing phase of the proprietary biomarker test for depression and to commercialization. The Board will provide further updates to the market regarding the appointment of a new CEO in due course.
お知らせ • Nov 23MYND Life Sciences Inc. Appoints Lana Hoogenboom to Its Board of DirectorsMYND Life Sciences Inc. announced the appointment of Lana Hoogenboom to its board of directors. Throughout her career, Lana Hoogenboom has held key positions in the pharmaceutical industry and has spent the last 12 years with Otsuka Canada. With extensive experience in the pharmaceutical sector and a proven track record in fostering relationships in the Pharmaceutical industry, Lana Hoogenboom will play a pivotal role in advancing the company's commercialization strategies and partnership initiatives. Lana's deep understanding of the complexities of the pharmaceutical landscape and the ability to expand market presence and develop innovative solutions for unmet needs.
お知らせ • Apr 06MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024MYND Life Sciences Inc., Annual General Meeting, Jun 06, 2024.
お知らせ • Feb 01MYND Life Sciences Inc. Appoints Laurie Bakke as an Independent Non-Executive DirectorMYND Life Sciences Inc. to welcome Ms. Laurie Bakke who was recently appointed to MYND's Board. Ms. Bakke joins as an independent non-executive director, bringing over 30 years of experience in the banking and finance industry to the Board. Ms. Bakke has extensive experience in domestic and international commercial finance with expertise in strategic direction, financial performance, risk and opportunity assessment, and business development. Ms. Bakke has led finance divisions for both privately held and publicly traded banks in the United States and Sweden. She possesses the ability to transform businesses, to generate targeted business and financial returns and to build high-performing teams.
お知らせ • Dec 07MYND Life Sciences Inc. Appoints Mr. John Campbell as Chief Executive OfficerMYND Life Sciences Inc. announced the immediate appointment of Mr. John Campbell as Chief Executive Officer. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
お知らせ • Dec 06MYND Life Sciences Inc. Appoints John Campbell as PresidentMYND Life Sciences Inc. Announced the Appointment of Mr. John Campbell as President. Mr. Campbell is distinguished for his expertise in financial services and brings a vast repertoire of experience in new business development, mergers, acquisitions, and corporate turnarounds. His pragmatic approach and strategic proficiency are evident in his guidance of professionals within competitive industries. Moreover, he was the President and Co-Founder of Odyssey Trust Company, a North American transfer agent that has effectively reshaped the industry's benchmarks for transfer agent and trust services. Mr. Campbell holds a Bachelor's Degree in Commerce, which he earned with distinction from the University of Alberta, and an ICD.D designation from the Institute of Corporate Directors.
お知らせ • Oct 27MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc.MYND Life Sciences Inc. (CNSX:MYND) entered into a non-binding letter of intent to acquire Cava Healthcare Inc. on October 25, 2023. The proposed merger will be preceded by independent third-party valuations of both companies. Arrangements within each company will be negotiated by subcommittees of unconflicted Directors from both CAVA and MYND and it will require affirmative votes by the Boards of Directors of both companies. It is anticipated the transaction will be completed in Q1 2024.
お知らせ • Jan 10MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023MYND Life Sciences Inc., Annual General Meeting, Mar 09, 2023.